Researchers have identified a potential new use for an existing osteoporosis drug in treating degenerative disc disease, a common cause of back pain. Scientists studying zebrafish with genetic mutations affecting collagen found that the animals developed mineral buildup and spinal fusion mimicking human disc degeneration. The team discovered that a faulty collagen-related gene triggered a chain reaction that hardened and deteriorated the spine's shock-absorbing discs.
The researchers successfully reduced spinal damage in these fish using a drug already approved for osteoporosis treatment. They also found that targeting fat metabolism helped limit disc degeneration. This dual approach suggests multiple intervention points for slowing or preventing this progressive disease.
The study leverages zebrafish as a genetic model because their spinal structure and disc composition closely resemble humans, making findings potentially translatable to people. Degenerative disc disease affects millions worldwide and currently has limited treatment options beyond pain management and surgery. The identification of genetic pathways driving mineral accumulation and disc hardening offers a roadmap for developing therapies.
The work builds on growing evidence that metabolic factors play a role in disc degeneration beyond simple wear and tear. By using a drug with an established safety profile in humans, researchers may accelerate the path to clinical testing. The next steps would involve confirming these mechanisms in mammalian models before human trials.
The findings underscore how studying rare genetic forms of disc disease can illuminate more common variants. Understanding the molecular underpinnings of spinal degeneration opens doors to preventive treatments that could help patients before irreversible damage occurs. This approach contrasts with current therapies that largely manage symptoms rather than address underlying disease mechanisms.